Home > Boards > Other Markets > Foreign Stock Markets > Antisoma (LSE:ASM)
Followed By 24
Posts 3088
Boards Moderated 0
Alias Born 01/18/2009

Saturday, June 05, 2010 6:37:55 AM

Re: None

Post# of 71
ASCO - Saturday June 5,

Long-term outcomes of responders in a randomized, controlled phase II trial of aptamer AS1411 in AML.

Sub-category: Leukemia
Category: Leukemia, Myelodysplasia, and Transplantation
Meeting: 2010 ASCO Annual Meeting
Citation: J Clin Oncol 28:7s, 2010 (suppl; abstr 6557)

Abstract No: 6557


Session: Leukemia, Myelodysplasia, and Transplantation
Type: General Poster Session
Time: Saturday June 5, 8:00 AM to 12:00 PM
Location: S Hall A2

http://abstract.asco.org/AbstView_74_49933.html

Conclusions:
This phase II trial suggested that addition of AS1411 to cytarabine may enhance anti-leukemic activity and that the combination has an acceptable safety profile in patients with relapsed and refractory AML.
Follow-up suggests substantial survival durations in some patients responding to AS1411 + cytarabine.
A phase IIb study is now evaluating responses, duration of responses and survival in AML patients randomized to AS1411 + cytarabine or cytarabine alone.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y